This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, S.-H. Articles by El-Deiry, W. S. Search for Related Content PubMed PubMed Citation Articles by Kim, S.-H. Articles by El-Deiry, W. S. Related Collections Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance

Mcl-1: A Gateway to TRAIL Sensitization

Laboratory of Molecular Oncology and Cell Cycle Regulation, Departments of Medicine (Hematology/Oncology), Genetics, Pharmacology, the Institute for Translational Medicine and Therapeutics and the Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Requests for reprints: Wafik S. El-Deiry, 415 Curie Boulevard, CRB 437, Philadelphia, PA 19104. Phone: 215-898-9015; Fax: 215-573-9139; E-mail: wafik{at}mail.med.upenn.edu.

Key Words: Mcl-1 • sorafenib • TRAIL

The proapoptotic cytokine tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is being evaluated presently as a selective anticancer agent, but its limited effects against cancer cell lines has raised some concerns about its ultimate clinical utility. Here, we review recent findings that cancer cell sensitivity to TRAIL is greatly increased when the Bcl-2 family protein Mcl-1 is down-regulated by the Raf/vascular endothelial growth factor kinase inhibitor sorafenib, a Food and Drug Administration–approved cancer drug. Using the TRAIL-sorafenib combination as a tactic to more effectively kill cancer cells may provide an effective tool to attack a variety of human cancers that are largely presently untreatable. [Cancer Res 2008;68(7):2062–4]

This article has been cited by other articles:

				U. M. Schneiders, L. Schyschka, A. Rudy, and A. M. Vollmar BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells Mol. Cancer Ther., October 1, 2009; 8(10): 2914 - 2925. [Abstract] [Full Text] [PDF]

				D.-L. Ou, Y.-C. Shen, J.-D. Liang, J.-Y. Liou, S.-L. Yu, H.-H. Fan, D.-S. Wang, Y.-S. Lu, C. Hsu, and A.-L. Cheng Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma Clin. Cancer Res., September 15, 2009; 15(18): 5820 - 5828. [Abstract] [Full Text] [PDF]

				R.-Y. Su, K.-H. Chi, D.-Y. Huang, M.-H. Tai, and W.-W. Lin 15-deoxy-{Delta}12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription Mol. Cancer Ther., October 1, 2008; 7(10): 3429 - 3440. [Abstract] [Full Text] [PDF]